VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
MEDP
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
MEDPMedpace Holdings, Inc.
$617.15$17.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
MEDP logo

Medpace Holdings, Inc.

MEDP
NASDAQ · Diagnostics & Research
$617.15
At close - Sep 23, 4:00 PM EDT - USD
Market Cap$17.23B
P/E40.4x
52W High$677.90
Volume272.67K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Decelerating Growth Offset by Strong Cash Generation

Medpace Holdings is experiencing a normalization from peak growth, with revenue growth decelerating from 32.0% in Q4 2025 to 17.2% in Q2 2026, yet it continues to outpace peers. The company maintains robust profitability with operating margins around 20.8% and...

GrowthDecelerating
ProfitabilityStable
ValuationReview
TechnicalsStrong
Explore valuation models
MARKET ACTION

MEDP price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

12/12 Beats

EPS beat 12 of last 12 quarters

02

Valuation risk

In Line

P/E is in line with peer median

03

Market leadership

RS 83 · Leader

High momentum (Outperforming 83% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Oct 22
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue growth decelerated to 17.2% YoY in Q2 2026 from a peak of 32.0% in Q4 2025, while gross margin contracted to 28.5% from 33.2% a year earlier, though operating margin remained stable at 20.8%.

Analyst Consensus-1.7% target
Hold(19 analysts)
4 Buy14 Hold1 Sell

The Bull Case

Upside Catalysts

Integrated CRO model

Medpace Holdings' full-service CRO model provides comprehensive clinical research solutions, driving efficiency and client retention.

Strong capital efficiency

The company's disciplined capital allocation and financial management have contributed to robust operational execution and stock appreciation.

Growth in biotech

Medpace Holdings is well-positioned to capitalize on the expanding biotech sector, leveraging its proprietary technology and expertise.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
MEDP+8.08%
S&P 500 (^GSPC)+12.39%
1-Year Return
MEDP+24.39%
S&P 500 (^GSPC)+15.77%
3-Year Return
MEDP+152.21%
S&P 500 (^GSPC)+71.85%
5-Year Return
MEDP+216.10%
S&P 500 (^GSPC)+64.76%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
40.4x
Forward P/EExpansion
35.1x
EV/EBITDA80th %ile
30.2x
FCF YieldCash Flow
4.0%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
40.4x
34.5x
80th· High
EV/EBITDA
30.2x
26.6x
80th· High
Price/FCF
25.3x
24.3x
80th· High
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$222.09-64.0%
Base (Fair)$396.34-35.3%
Bull$503.41-18.4%
$222.09 Bear$396.34 Base$503.41 Bull
Current Market Price: $617.15
Trades at a 55.7% premium to Base DCF ($396.34)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue
$2.53B+20.0% YoY
Net income
$451M+11.6% YoY
Free cash flow
$682M+19.2% YoY
Operating margin
21.1%-0.0 pts YoY
ROIC (TTM)154.9%
Avg ROIC 5Y-
ROE (TTM)70.2%
Piotroski Score6 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate12/12 (100%)
Revenue Beat Rate7/12 (58%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Jul 22, 2026
$4.25+6.8%
vs $3.98
$707M+2.6%
vs $690M
Q2 2026
Apr 22, 2026
$4.28+9.2%
vs $3.92
$707M+1.3%
vs $698M
Q1 2026
Feb 9, 2026
$4.67+11.5%
vs $4.19
$708M+2.8%
vs $689M
Q4 2025
Oct 22, 2025
$3.86+9.3%
vs $3.53
$660M+2.9%
vs $641M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

5 Stories
Business Wire·1d ago
Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2026 financial results after the market close on Wednesday, October 21, 2026. The Company will host a conference call the following morning, Thursday, October 22, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended yo.

Zacks Investment Research·2d ago
Medpace (MEDP) Outperforms Broader Market: What You Need to Know

Medpace (MEDP) concluded the recent trading session at $624.2, signifying a +1.94% move from its prior day's close.

Defense World·5d ago
Medpace Holdings, Inc. $MEDP Stock Position Decreased by Integrated Wealth Concepts LLC

Integrated Wealth Concepts LLC trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) by 29.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,287 shares of the company's stock after selling 936 shares during the quarter.

Defense World·Sep 15, 2026
Medpace Holdings, Inc. $MEDP Stock Position Decreased by Engineers Gate Manager LP

Engineers Gate Manager LP lowered its stake in Medpace Holdings, Inc. (NASDAQ: MEDP) by 62.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,693 shares of the company's stock after selling 7,670 shares during the quarter. Engineers Gate Manager LP's

Filtered for Medpace Holdings, Inc.More Headlines
04

Compare before deciding

Benchmark MEDP against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Medpace Holdings, Inc. (MEDP)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
MEDP logoMEDPMedpace Holdings, Inc.Current
$617.15$17.23B40.3919.97%17.83%70.23%—
ICLR logoICLRICON Public Limited Company
$163.90$12.55B56.52-0.37%3.99%3.54%—
CRL logoCRLCharles River Laboratories International, Inc.
$277.33$13.36B-95.30-0.85%-5.96%-7.63%—
PRA logoPRAProAssurance Corporation
$25.00$1.29B25.25-2.67%6.04%4.95%—
HIMS logoHIMSHims & Hers Health, Inc.
$28.39$6.33B55.6759%-5.51%-30.03%—
IQV logoIQVIQVIA Holdings Inc.
$267.86$44.09B34.175.87%8.1%21.51%—

Compare MEDP vs Peers

Medpace Holdings, Inc. (MEDP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ICLR

Most directly comparable listed peer for MEDP.

Scale Benchmark

vs TMO

Larger-name benchmark to compare MEDP against a more recognizable public peer.

Peer Set

Compare Top 5

vs ICLR, CRL, PRA, HIMS

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

MEDP SEC Filings & Documents

Medpace Holdings, Inc. (MEDP) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Jul 22, 2026·SEC

Material company update

Jun 4, 2026·SEC

Material company update

May 19, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 10, 2026·SEC

FY 2025

Feb 11, 2025·SEC

FY 2024

Feb 13, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Jul 23, 2026·SEC

FY 2026

Apr 23, 2026·SEC

FY 2025

Oct 23, 2025·SEC

Get notified when MEDP posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

MEDP Frequently Asked Questions

Medpace Holdings, Inc. (MEDP) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Medpace Holdings, Inc.'s revenue?

Medpace Holdings, Inc. (MEDP) reported $2.78B in revenue for fiscal year 2025. This represents a 859% increase from $290.0M in 2014.

How fast is Medpace Holdings, Inc. growing?

Medpace Holdings, Inc. (MEDP) grew revenue by 20.0% over the past year. This is strong growth.

Is MEDP profitable?

Yes, Medpace Holdings, Inc. (MEDP) is profitable, generating $491.5M in net income for fiscal year 2025 (17.8% net margin).

Dividend & Returns
What is MEDP's return on equity?

Medpace Holdings, Inc. (MEDP) has a return on equity (ROE) of 70.2%. This is excellent, indicating efficient use of shareholder capital.

What is Medpace Holdings, Inc.'s free cash flow?

Medpace Holdings, Inc. (MEDP) generated $733.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in MEDP back in 2014?

Total return calculator · dividends reinvested · 12+ years of data

See returns →